SABS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 22:00):

Stats
Dagens volum	329.00
Gjennomsnittsvolum	13 334.00
Markedsverdi	37.82M
EPS	$0 ( 2024-04-01 )
Neste inntjeningsdato	( $0 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.540
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-21	Kropotova Alexandra	Buy	140 000	Employee Stock Option (right to buy)
2024-02-21	Sullivan Eddie Joe	Buy	190 000	Employee Stock Option (right to buy)
2024-02-21	Bausch Christoph Lawrence	Buy	140 000	Employee Stock Option (right to buy)
2024-02-21	King Michael	Buy	115 000	Employee Stock Option (right to buy)
2024-02-21	Reich Samuel J	Buy	434 000	Employee Stock Option (right to buy)

INSIDER POWER
70.14
Last 88 transactions
Buy: 19 783 333 \| Sell: 3 137 658

SAB Biotherapeutics, Inc. Korrelasjon

10 Mest positive korrelasjoner
SHBI	0.924
RXT	0.912
POTX	0.907
MVST	0.905
WSBC	0.902
VNDA	0.9
BCAB	0.9
SPFI	0.899
OPHC	0.898
UCBI	0.897

10 Mest negative korrelasjoner
RMRM	-0.93
APOP	-0.915
IIN	-0.882
EXFO	-0.881
TIG	-0.874
MLVF	-0.873
AUPH	-0.872
EVCM	-0.871
SUMR	-0.871
CARG	-0.869

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

SAB Biotherapeutics, Inc. Økonomi

Annual	2023
Omsetning:	$2.24M
Bruttogevinst:	$-1.51M (-67.28 %)
EPS:	$-7.64

FY	2023
Omsetning:	$2.24M
Bruttogevinst:	$-1.51M (-67.28 %)
EPS:	$-7.64

FY	2022
Omsetning:	$23.90M
Bruttogevinst:	$20.61M (86.23 %)
EPS:	$-4.31

FY	2021
Omsetning:	$60.88M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.394

Financial Reports:

No articles found.

SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.